ArticleJournal of neurology, neurosurgery, and psychiatry1998
Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
Article in Journal of neurology, neurosurgery, and psychiatry, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Peripheral Blood and Cerebrospinal Fluid Cytokine Levels in Guillain Barré Syndrome: A Systematic Review and Meta-Analysis.Frontiers in neuroscience · 2019Pooled it
- Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study.Critical care (London, England) · 2011Trial
- Uremic Peripheral Neuropathy in Nondiabetic Chronic Hemodialysis Patients.Annals of Indian Academy of Neurology · 2025Article
- Experimental Autoimmune Neuritis Nerve Demyelination Is Attenuated by Blocking JAK2/STAT3 Signaling Pathway in Rats.Brain and behavior · 2025Article
- Review
- Progress in Guillain-Barré syndrome immunotherapy-A narrative review of new strategies in recent years.Human vaccines & immunotherapeutics · 2023Review
- The effects of vasoactive intestinal peptide in the rat model of experimental autoimmune neuritis and the implications for treatment of acute inflammatory demyelinating polyradiculoneuropathy or Guillain-Barré syndrome.Drug design, development and therapy · 2018Article
- Biological Drugs in Guillain-Barré Syndrome: An Update.Current neuropharmacology · 2017Review
- Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.Mediators of inflammation · 2015Review
- Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease.Journal of neuroinflammation · 2012Article
- Immunopathology and Th1/Th2 immune response of Campylobacter jejuni-induced paralysis resembling Guillain-Barré syndrome in chicken.Medical microbiology and immunology · 2012Article
- The role of cytokines in Guillain-Barré syndrome.Journal of neurology · 2011Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo delineate the possible implication of the immunosuppressive cytokine transforming growth factor beta 1 (TGF-beta1) in the pathogenesis of Guillain-Barré syndrome. Guillain-Barré syndrome is a disorder that may implicate cytokines in its pathogenesis. TGF-beta1 is a potent anti-inflammatory cytokine occasionally shown to be regulated in the course of demyelinating disorders.
methodsThe study measured circulating proinflammatory and anti-inflammatory cytokines from the progressing phase to early recovery in patients with Guillain-Barré syndrome. Plasma concentrations of TNF-alpha, IL-beta1, IL-2, IL-4, IL-6, IL-10, and TGF-beta1 were prospectively evaluated in 15 patients with Guillain-Barré syndrome every three days for the first 15 days after admission to hospital, and in 15 controls with non-inflammatory neurological diseases.
resultsConcentrations of TGF-beta1 in plasma were decreased in 13115 patients (87 %) at day 1, remained low during progression and the plateau of paralysis (days 1-10), and then progressively increased up to control concentrations during early recovery (days 12-15). Concentrations of plasma TGF-beta1 correlated positively with motor function, the lowest values being e found in the most disabled patients. Concentrations of plasma TGF-beta1 were decreased before any treatment, and during treatment by either plasma exchange or intravenous immunoglobulins, plasma exchange being associated with a more pronounced decrease in TGF-beta1 at day 7. Circulating TNF-alpha concentrations were raised, as previously reported, when other cytokines were either randomly increased (IL-2, IL-6), or undetectable (IL-1, IL-4, IL-7, IL-10).
conclusionsDown regulation of TGF-beta1 in the early course of Guillain-Barré syndrome could participate in neural inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.